Trial Profile
Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2011 New trial record